Orencia (abatacept) for Intravenous Use
Customize your policy alerts
Sign up for all Bluecross Idaho policy alerts
Know when Bluecross Idaho releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage under the medical benefit for intravenous Orencia (abatacept), including initial and continuation authorization criteria, dosing, and investigational uses. Subcutaneous abatacept is managed under the pharmacy benefit.
A statement regarding National Comprehensive Cancer Network (NCCN) indications was added.
Criteria related to tuberculosis infections and tuberculosis screening were clarified.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.